Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania

被引:172
作者
Frey, Benicio N.
Andreazza, Ana C.
Cereser, Keila M. M.
Martins, Marcio R.
Valvassori, Samira S.
Reus, Gislaine Z.
Quevedo, Joao
Kapczinski, Flavio
机构
[1] Hosp Clin Porto Alegre, Biopolar Disorders Program, Ctr Pesquisas, BR-90035003 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Dept Biochem, BR-90035003 Porto Alegre, RS, Brazil
[3] Univ Extremo Catarinese, Lab Neurociencias, BR-88806000 Criciuma, SC, Brazil
关键词
amphetamine; bipolar disorder; brain-derived neurotrophic factor; lithium; mania; valproate;
D O I
10.1016/j.lfs.2006.01.002
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
There is an emerging body of data suggesting that mood disorders are associated with decreased brain-derived neurotrophic factor (BDNF). The present study aims to investigate the effects of the mood stabilizers lithium (Li) and valproate (VPT) in an animal model of bipolar disorder. In the first experiment (acute treatment), rats were administered D-amphetamine (AMPH) or saline for 14 days, and then between day 8 and 14, rats were treated with either Li, VPT or saline. In the second experiment (maintenance treatment), rats were pretreated with Li, VPT or saline, and then between day 8 and 14, rats were administered AMPH or saline. In both experiments, locomotor activity was measured using the open-field test and BDNF levels were measured in rat hippocampus by sandwich-ELISA. Li and VPT reversed AMPH-induced behavioral effects in the open-field test in both experiments. In the first experiment, Li increased BDNF levels in rat hippocampus. In the second experiment, AMPH decreased BDNF levels and Li and VPT increased BDNF levels in rat hippocampus. Our results suggest that the present model fulfills adequate face, construct and predictive validity as an animal model of mania. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 41 条
[1]   Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients [J].
Anand, A ;
Verhoeff, P ;
Seneca, N ;
Zoghbi, SS ;
Seibyl, JP ;
Charney, DS ;
Innis, RB .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (07) :1108-1114
[2]  
AYLMER CGG, 1987, PSYCHOPHARMACOLOGY, V91, P198
[3]   Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade [J].
Beaulieu, JM ;
Sotnikova, TD ;
Yao, WD ;
Kockeritz, L ;
Woodgett, JR ;
Gainetdinov, RR ;
Caron, MG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (14) :5099-5104
[4]   A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania [J].
Bebchuk, JM ;
Arfken, CL ;
Dolan-Manji, S ;
Murphy, J ;
Hasanat, K ;
Manji, HK .
ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (01) :95-97
[5]   Lithium and valproate attenuate dextroamphetamine-induced changes in brain activation [J].
Bell, EC ;
Willson, MC ;
Wilman, AH ;
Dave, S ;
Asghar, SJ ;
Silverstone, PH .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2005, 20 (02) :87-96
[6]   Medical progress: Bipolar disorder [J].
Belmaker, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :476-486
[7]   Neuronal pathology in the hippocampal area of patients with bipolar disorder: A study with proton magnetic resonance spectroscopic imaging [J].
Bertolino, A ;
Frye, M ;
Callicott, JH ;
Mattay, VS ;
Rakow, R ;
Shelton-Repella, J ;
Post, R ;
Weinberger, DR .
BIOLOGICAL PSYCHIATRY, 2003, 53 (10) :906-913
[8]   The neurobiology of bipolar disorder: Focus on signal transduction pathways and the regulation of gene expression [J].
Bezchlibnyk, Y ;
Young, LT .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2002, 47 (02) :135-148
[9]   Neuroprotective effects of lithium in cultured cells and animal models of diseases [J].
Chuang, DM ;
Chen, RW ;
Chalecka-Franaszek, E ;
Ren, M ;
Hashimoto, R ;
Senatorov, V ;
Kanai, H ;
Hough, C ;
Hiroi, T ;
Leeds, P .
BIPOLAR DISORDERS, 2002, 4 (02) :129-136
[10]   Finding the intracellular signaling pathways affected by mood disorder treatments [J].
Coyle, JT ;
Duman, RS .
NEURON, 2003, 38 (02) :157-160